CDC Website CDC Website

To Join the NPIN community or

Home » Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R21 Clinical Trial Not Allowed)

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R21 Clinical Trial Not Allowed)

The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV. This program covers two parallel FOAs of identical scientific scope. This FOA solicits applications for exploratory/developmental projects using the NIH R21 mechanism. The companion FOA, RFA-CA-18-013, is a parallel announcement for well-developed research projects using the NIH R01 funding mechanism.

Funding Organization
Locations
National
Eligible Organizations
Number of Awards Given
4-6 awards.
Award Amount Notes
Direct costs are limited to $275,000 over a two-year period, with no more than 200,000 in direct costs allowed in any single year. Application budgets should reflect the actual needs of the proposed project.
Letter of Intent Date
5/18/18
Application Due Date
8/16/18
Open Ended Date
7/16/18
Project Start Date
4/1/19
Application Contact
Shane
Woodward
Branch B Chief, Grants Portfolio Management
240-276-6303
woodwars@mail.nih.gov
Technical Contact
Rebecca
L
Huppi, PhD
Program Director
liddellr@exchange.nih.gov
240-781-3324
Fund Duration
The scope of the proposed project should determine the project period. The maximum project period is 2 years.
Subjects
Audiences
Focus Area

Fund Number: 

5381

Fund ID: 

RFA-CA-18-014

Last Updated: 

5/18/18